This week in North Dakota, health officials are sending their first Johnson & Johnson Kovid-19 vaccine to pharmacies and urgent care clinics, where only those with regular doctors are not able to receive a single jab. In Missouri, dosing is going on in community health centers and rural hospitals. And in North Carolina, health providers are using it in meatpacking, farm and grocery workers vaccinations.
Since Johnson & Johnson Data detected While showing that its vaccine, while highly protective, had slightly lower efficacy rates than earlier shots produced by Modern and Pfizer-BioNotech, health officials have feared that the new shot may be viewed as an inferior choice by some Americans. Can.
But the opening days of its rollout reveal something different: Some people are eager to get it because they want the convenience of a shot. And public health officials are excited about how fast they can get a shot delivered, especially in vulnerable communities that might not otherwise have access to the vaccine.
“This is a potential success,” Dr. Louisiana’s top health officer Drs. Said Joseph Canter. With its first allocated dose, the state is conducting a dozen large Johnson & Johnson vaccination programs at Civic Centers and other public places that have been created after working for the flu vaccine.
As Johnson & Johnson’s production picks up over the next few months, Drs. Kanter said the shot would allow his state to cut costs for staffing and operations related to the second dose: “The J&J vaccine brings a lot to the table.”
How well it was judged Prevents critical illness, hospitalization and deathJohnson & Johnson Schott is comparable to those made by Modern and Pfizer-BioNtech. And although its overall efficacy rate in the US is low – 72 percent, while for others, about 95 percent – experts say comparing these numbers is problematic because the companies’ tests are conducted at different locations at different times. it was done.
The Johnson & Johnson vaccine can also be kept at normal refrigeration temperatures for three months – ideal for distribution at nonmedical sites such as stadiums and conference centers.
Kaiser Permanente is a senior investigator at the Colorado Institute of Health Research and a member of the Center for Disease Control and Prevention. “There are circumstances in which this is a really good option or perhaps the best option,” said Matthew Delhi. Independent Vaccine Advisory Committee.
Only four million doses were sent this week, and Company manufacturing gaps This means that it will be at least a month before states begin receiving significant supplies. Because of that difference, state officials are considering the first wave of doses as a moment to test various ways to deploy them.
Oregon Health Authority director Patrick Allen said the first dose in the state went into a variety of settings, “to see if we learn anything from its use.” Those include large-scale vaccination sites around Portland, adult foster care homes, and pharmacies that were not included in the federal government’s pharmacy program. Health officials will evaluate the success of each of the sites that will formulate plans for large shipments.
Many state health officials said they were focused on vaccinating people who may find it harder to reach a second dose, such as those who are homeless or on the verge of release from prison. In North Carolina, the category includes mobile agricultural communities with three or four-week work seasons in the state. State Health Secretary Mandy Cohen said large meatpacking plants in the state, such as Smithfield and Tyson Foods, were interested in the Johnson & Johnson vaccine and were in consultation with their department.
And because the vaccine has fewer side effects than other options, it’s appealing to people who don’t want to risk missing a day of work to overcome a cold or fever, she said: “A lot of people Hai Joe is like, ‘I’m more interested now that you tell me that I only have to take a shot once instead of two. “
“I don’t think it’s an inferior vaccine, and that’s why I’m taking it for myself,” said Ms. Cohen, who was scheduled to shoot Johnson & Johnson on Friday.
In small, independent pharmacies, the vaccine has caused excitement. Steve Hoffert, owner of Magnolia Pharmacy in Magnolia, Texas, a small town in Houston, has received phone calls and emails from residents anticipating this week’s arrival. He said he hopes to hold a Johnson & Johnson event for teachers on 13 March. Area schools have struggled to find substitute teachers during the epidemic, and a vaccine that does not require a second visit was an important development for much of the time, he said.
Tim and Joyce Staub, who live in Chillicote, Ohio, a city of about 20,000 hours’ drive from Columbus, were two of the first Americans to receive the Johnson & Johnson vaccine. Normal vaccinations in both were to occur in the following week. But then he received notice on Wednesday that an independent pharmacy near him had received 100 doses of Johnson & Johnson’s shot. Ms. Staub, 68, hesitates about needles and prefers a one-to-one approach.
Mr. Staub, 67, said he felt the vaccine was a better option for the health providers where he received it. “They don’t have the resources, I don’t think, to store vaccines is really hard,” he said.
States are able to adapt and tinker with distribution plans in part because the federal government did not issue pre-determined guidelines for where and to whom the vaccine should go.
This winter, near the Food and Drug Administration authority of the Johnson & Johnson Vaccine, federal officials involved in vaccine distribution pushed the shot to be used in a more centralized way, either in large stadiums and large ones run by the Federal Emergency. Vaccination sites According to officials familiar with these discussions, the management agency or only in pharmacies. But the White House preferred to allow states to formulate their own plans, as they did for the Modern and Pfizer-BioNotech vaccines.
Although health experts are excited about the potential public health benefits of the new vaccine, some also fear that the public interest will decrease once the vaccine is reduced. If given a choice between brands, some may reject Johnson & Johnson, seeing it as an inferior choice.
In black churches in the mid-winter region, this winter, Darrell J., a professor of health policy at Johns Hopkins University. Gaskin and Rupali Limaye, a scientist at the university who studies vaccine hesitancy, consulted and convinced hundreds of people. Pastors and congregation members of the African Methodist Episcopal Zion emphasized the safety of the Johnson & Johnson Vaccine and the prevention and death of severe Kovid-19 in virtual presentations, including the Black Volunteers in the company’s trial.
Dr. Gaskin said it was important to emphasize the benefits of the vaccine to officials at the beginning of its distribution, so people “don’t feel like there’s a luxury vaccine and then a non-luxury vaccine.”
“We are facing oddities related to Kovid,” Drs. Limaye said. “How do we reduce inequalities? We get a product that is a dose and it is stable. “
Patricia Cooper, a teacher in Washington DC, dau. One of the members of Gaskin’s church said that President Donald J. Trump’s efforts to claim credit for a vaccine last year and the “Emergency Use Authority” label suggested to him that the federal government review the vaccines, given his irritability about his safety. But she said she was eager to receive a vaccine, most notably Johnson & Johnson.
“This one is more attractive to me,” he said. “Who likes to be stuck more than once?”
But Oregon health officer Mr. Allen cautioned that using it in more specific ways could lead to doubts over its quality.
“If you start being a little too cute about targeting its use, you can possibly feed disbelief, ‘Well, why am I getting that vaccine? And, I’m in this particular population and who People are not in this special population, they are not getting this vaccine. ‘
Federal health officials have promised a way to crack down on the Johnson & Johnson vaccine that is likely to be used in disproportionate ways. The chair of the new health equity task force of the Biden administration, Drs. Marcella Nunz-Smith said at a White House news conference this week that the distribution of the vaccine “must also occur in communities.”
“We will do biometric tracking, such as zip codes and social vulnerabilities, to see where the vaccines are going,” she said. “And should some vaccines go to certain communities consistently, we will be able to intervene.”
Some state officials believe that the pairing of new and old vaccines may help show that they are equally important.
Mr. Allen said that Oregon was creating similar distribution plans for Johnson & Johnson and Modern because both vaccines could be stored in refrigerators for the short term. He said the state is treating the Pfizer-Bayonet vaccine with “special consideration” for its strict shipping requirements and large packages of vials for large-scale vaccination sites.
The vaccine is being managed in a similar way from Johnson & Johnson and Modern, he said, “will help avoid equity questions and potential concerns, based on perceived differences between vaccines, some of which are genuine and some of which Are not. “